SCHEMBL1334159

SCHEMBL1334159

COc1cc(N2CCN(C)CC2)ccc1C(=O)Nc1n[nH]c2ccc(OCc3c(F)ccc(F)c3Cl)cc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 12/20 0.65
NTRK1 P04629 3/20 0.65
PLK4 O00444 1/20 0.65
DAPK3 O43293 1/20 0.65
PRKCG P05129 1/20 0.65
ROS1 P08922 1/20 0.65
FER P16591 1/20 0.65
LTK P29376 1/20 0.65
WEE1 P30291 1/20 0.65
FRK P42685 1/20 0.65
MAPK8 P45983 1/20 0.65
MST1R Q04912 1/20 0.65
PTK2 Q05397 1/20 0.65
TNK2 Q07912 1/20 0.65
NTRK3 Q16288 1/20 0.65
DYRK1B Q9Y463 1/20 0.65
MAP4K5 Q9Y4K4 1/20 0.65
FGFR1 P11362 4/20 0.57
KIT P10721 2/20 0.54
FLT3 P36888 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1336567 0.91 NTRK1 (0.60) ALKNTRK1PLK4DAPK3PRKCG
SCHEMBL1336372 0.89 NTRK1 (0.71) ALKNTRK1FGFR1KITFLT3
SCHEMBL1334201 0.87 NTRK1 (0.60) ALKNTRK1PLK4DAPK3PRKCG
SCHEMBL1336562 0.86 KIT (0.67) ALKNTRK1PLK4DAPK3PRKCG
SCHEMBL12125340 0.83 ALK (0.76) ALKNTRK1PLK4DAPK3PRKCG
Hydrochloric Acid SCHEMBL1336524 0.82 ALK (0.75) ALKNTRK1PLK4DAPK3PRKCG
SCHEMBL12125337 0.81 ALK (0.66) ALKNTRK1PLK4DAPK3PRKCG
SCHEMBL1334245 0.80 ALK (0.66) ALKNTRK1PLK4DAPK3PRKCG
Hydrochloric Acid SCHEMBL1336498 0.80 ALK (0.65) ALKNTRK1PLK4DAPK3PRKCG
SCHEMBL14641982 0.80 NTRK1 (0.67) ALKNTRK1FGFR1KITFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373626-B1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-08-24 EP claimed
US-8354399-B2 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-01-15 US claimed
US-20110281843-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-11-17 US claimed
EP-2373626-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2011-10-12 EP claimed
WO-2010069966-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO claimed
EP-2373626-B1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-08-24 EP disclosed
EP-2373626-B1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-08-24 EP disclosed
US-8354399-B2 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-01-15 US disclosed
US-8354399-B2 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-01-15 US disclosed
US-8354399-B2 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-01-15 US disclosed
US-20110281843-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-11-17 US disclosed
US-20110281843-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-11-17 US disclosed
US-20110281843-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-11-17 US disclosed
WO-2010069966-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281843-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, MAP3K3, MAP3K5 ALK 401/4885NTRK1 1510/4885PLK4 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.